Courage Therapeutics Secures Undisclosed Seed Funding Led by Arsenal Bridge Ventures

Why It Matters

The infusion of seed capital positions Courage Therapeutics to advance its obesity‑focused pipeline, a high‑growth therapeutic area, and signals investor confidence in emerging metabolic‑targeted modalities. Successful development could add a new class of treatments to a market projected to exceed $30 billion globally.

Deal Summary

Ann Arbor‑based biopharma Courage Therapeutics announced the close of an undisclosed seed round, bringing its total funding to over $11 million. The round was led by Arsenal Bridge Ventures with participation from existing investors, and will be used to expand operations and advance its obesity‑focused drug pipeline.